Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EMA accepts Sandoz’s MAA for biosimilar to Pfizer’s Enbrel drug
Novartis unit Sandoz is seeking approval for all indications included in the label of the reference product. More than 120 million people in the European Union are living
Novartis unit Sandoz is seeking approval for all indications included in the label of the reference product. More than 120 million people in the European Union are living
The new therapies will be developed using BioAtla’s conditionally active biologics (CAB) platform and Pfizer’s antibody drug conjugate (ADC) payloads. The deal gives both companies a license to
The financing, which was supported by institutional investors in the US and Europe, will support the continued clinical development of the company’s ERY-ASP/GRASPA. ERY-ASP/GRASPA is designed specifically to
Evofosfamide, earlier known as TH-302, failed to improve overall survival when combined with chemotherapy in the two indications. Evofosfamide is an investigational hypoxia-activated prodrug of a bis-alkylating agent
The program is part of a collaboration between AstraZeneca and its worldwide biologics research and development unit MedImmune. It is intended at developing and commercializing durvalumab across various
Earlier this year, the company said it would delay its regulatory submission for basal insulin peglispro (BIL), the potential once-daily type 1 and type 2 diabetes treatment. The
The data supporting the application was generated in the four Phase 3 Astral clinical trials. Of the 1,035 patients treated with SOF/VEL for 12 weeks, 1,015 achieved the
The initial phase-one study will combine Amgen’s Blincyto (blinatumomab) with Merck’s Keytruda (pembrolizumab) to treat patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma.
The candidate is the fourth to be advanced from the company’s development pipeline in the last year, with the program reaching development stage under two years. Redx Pharma
The companies agreed to further develop Zymeworks’ Effector Function Enhancement and Control Technology (EFECT) platform by designing, engineering, and testing new engineered Fc domains with specific antibody-mediated immune